Abstract
The efficacy of a heat inactivated hepatitis B virus vaccine, containing 3 micrograms hepatitis B surface antigen (HBsAg), was studied in a high risk group of 800 susceptible homosexual men by a randomised placebo controlled double blind trial. At the trial end point (21.5 months), 17 hepatitis B virus infections had occurred in vaccinated subjects (attack rate 4.8%) and 56 in subjects receiving a placebo (attack rate 23.8%). This reduction in the incidence of hepatitis B virus infections in vaccinated subjects was highly significant (p less than 0.0001). Two months after the first injection 72.3% of the vaccinated subjects had formed antibodies against hepatitis B surface antigen, and this percentage increased to 89% at four months. Maximum anti-HBs titres were reached five months after the first vaccination, the geometric mean titre being 107.6 mIU. Even vaccinated subjects with a low antibody response (greater than or equal to 1 and less than 10 mIU) were found to be protected from HBsAg-positive infections. The vaccine had no serious side effects.
Full text
PDF
Images in this article
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- BERKSON J., GAGE R. P. Calculation of survival rates for cancer. Proc Staff Meet Mayo Clin. 1950 May 24;25(11):270–286. [PubMed] [Google Scholar]
- Coutinho R. A., Schut B. J., Albrecht-Van Lent N. A., Reerink-Brongers E. E., Jesdijk L. S. Hepatitis B among homosexual men in The Netherlands. Sex Transm Dis. 1981 Oct-Dec;8(4 Suppl):333–335. [PubMed] [Google Scholar]
- Francis D. P., Hadler S. C., Thompson S. E., Maynard J. E., Ostrow D. G., Altman N., Braff E. H., O'Malley P., Hawkins D., Judson F. N. The prevention of hepatitis B with vaccine. Report of the centers for disease control multi-center efficacy trial among homosexual men. Ann Intern Med. 1982 Sep;97(3):362–366. doi: 10.7326/0003-4819-97-3-362. [DOI] [PubMed] [Google Scholar]
- Lee E. T., Desu M. M. A computer program for comparing K samples with right-censored data. Comput Programs Biomed. 1972 Nov;2(4):315–321. doi: 10.1016/0010-468x(72)90019-0. [DOI] [PubMed] [Google Scholar]
- Schreeder M. T., Thompson S. E., Hadler S. C., Berquist K. R., Zaidi A., Maynard J. E., Ostrow D., Judson F. N., Braff E. H., Nylund T. Hepatitis B in homosexual men: prevalence of infection and factors related to transmission. J Infect Dis. 1982 Jul;146(1):7–15. doi: 10.1093/infdis/146.1.7. [DOI] [PubMed] [Google Scholar]
- Szmuness W., Much I., Prince A. M., Hoofnagle J. H., Cherubin C. E., Harley E. J., Block G. H. On the role of sexual behavior in the spread of hepatitis B infection. Ann Intern Med. 1975 Oct;83(4):489–495. doi: 10.7326/0003-4819-83-4-489. [DOI] [PubMed] [Google Scholar]
- Szmuness W., Stevens C. E., Harley E. J., Zang E. A., Oleszko W. R., William D. C., Sadovsky R., Morrison J. M., Kellner A. Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States. N Engl J Med. 1980 Oct 9;303(15):833–841. doi: 10.1056/NEJM198010093031501. [DOI] [PubMed] [Google Scholar]
- Szmuness W., Stevens C. E., Zang E. A., Harley E. J., Kellner A. A controlled clinical trial of the efficacy of the hepatitis B vaccine (Heptavax B): a final report. Hepatology. 1981 Sep-Oct;1(5):377–385. doi: 10.1002/hep.1840010502. [DOI] [PubMed] [Google Scholar]